Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

14.26
-1.5600-9.86%
Post-market: 14.330.0700+0.49%17:51 EST
Volume:2.68M
Turnover:41.05M
Market Cap:312.45M
PE:-0.04
High:16.80
Open:16.17
Low:14.06
Close:15.82
52wk High:65.80
52wk Low:2.62
Shares:21.91M
Float Shares:18.97M
Volume Ratio:0.83
T/O Rate:14.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-342.6591
EPS(LYR):-34.0333
ROE:-125.43%
ROA:-144.27%
PB:-0.14
PE(LYR):-0.42

Loading ...

Vor Bio price target lowered to $32 from $55 at H.C. Wainwright

TIPRANKS
·
Nov 14

UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate

Benzinga
·
Nov 14

Vor Biopharma Q3 EPS $(121.63) May Not Compare To $(3.32) Estimate

Benzinga
·
Nov 14

Vor Biopharma reports third quarter loss and reduced R&D expenses

Reuters
·
Nov 14

Vor Biopharma Announces $93.7 Million Public Offering

TIPRANKS
·
Nov 12

Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump

Benzinga
·
Nov 12

Vor Biopharma Shares Fall 46.9% After Steeply Discounted $100 Mln Stock Offering

THOMSON REUTERS
·
Nov 11

BUZZ-U.S. STOCKS ON THE MOVE-Nebius, Estee Lauder, Soleno

Reuters
·
Nov 11

Top Premarket Decliners

MT Newswires Live
·
Nov 11

Vor Biopharma Shares Down 27.9% Premarket After Launching $100 Mln Stock Offering

THOMSON REUTERS
·
Nov 11

BRIEF-Vor Bio Prices Public Offering Of 10 Million Shares At $10 Each

Reuters
·
Nov 11

Vor Biopharma Inc - Prices Public Offering of 10 Mln Shares at $10 Each

THOMSON REUTERS
·
Nov 11

Vor Bio Stock Slides on Public Offering

Dow Jones
·
Nov 11

Vor Biopharma Shares Extend After-Hours Losses; Last Down 27.1%

THOMSON REUTERS
·
Nov 11

BUZZ-Vor Biopharma plunges after $100 mln stock offering launch

Reuters
·
Nov 11

Vor Bio announces $100M common stock offering

TIPRANKS
·
Nov 11

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

THOMSON REUTERS
·
Nov 11

Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)

TIPRANKS
·
Nov 10

Vor Bio achieves primary endpoint in Stage A of Phase 3 study of telitacicept

TIPRANKS
·
Nov 10

BRIEF-Vor Biopharma Says Primary Endpoint Achieved In Phase 3 Clinical Study Evaluating Telitacicept

Reuters
·
Nov 09